Skip to content
Home
John G. Frelinger, Ph.D.

John G. Frelinger, Ph.D.

Contact

Office (585) 275-3405

Looking for more Information?

Visit my lab website to learn more about my research, collaborators, latest news, etc.

Visit Research Lab Website

About Me

Faculty Appointments

Professor Emeritus - Department of Microbiology and Immunology (SMD)

Credentials

Post-doctoral Training & Residency

Senior Postdoctoral Fellow, American Cancer Society, California Division, Stanford University. Mentor: Dr. C.G. Fathman, Immunology 1983 - 1984

Jane Coffin Childs Fellow, Immunology, Stanford University, Mentor: Dr. C.G. Fathman, Immunology 1981 - 1983

NIH Postdoctoral Fellow, Caltech, Pasadena, CA. Mentor: Dr. Leroy Hood, Molecular Biology 1980 - 1981

Education

PhD | California Institute of Technology. Biochemistry. 1980

BS with Distinction and Departmental Honors | Stanford University. Biology. 1975

Awards

Special Commendation Teaching First year Medical School. 2020

Manuel D. Goldman Prize for Excellence in Teaching Medical School. 2016

Special Commendation for Teaching-Medical School. 2015

Chair Education Committee (AAI). 2014

Alumni Gold Medal Teaching Award. 2012

AAI Education Committee. 2011 - 2014

Special Commendation Teaching-Medical School. 2002

Faculty Speaker, Medical School Class of 2000 Awards Ceremony. 2000

Distinguished Speaker. 2000

Herbert W. Mapstone Prize for Teaching Excellence. 1998

Special Commendation Teaching-Medical School. 1996

Herbert W. Mapstone Prize for Teaching Excellence. 1995

Special Commendation Teaching-Medical School. 1994

Andrew W. Mellon Deans Teaching Scholar. 1991 - 1993

Junior Faculty Research Award. 1986 - 1988

American Cancer Society Senior Fellowship, California Division. 1983 - 1984

Jane Coffin Childs Fellowship. 1981 - 1983

B.S. with Distinction and Departmental Honors. 1975

National Merit Scholarship. 1971 - 1975

Research

My laboratory has a number of interests united by the common theme of T cell recognition. One focus of research has been the generation and maintenance of effective T cell responses to tumors. It has become apparent that anti-tumor responses can be directed against differentiation antigens. Thus, ev...
My laboratory has a number of interests united by the common theme of T cell recognition. One focus of research has been the generation and maintenance of effective T cell responses to tumors. It has become apparent that anti-tumor responses can be directed against differentiation antigens. Thus, even with multiple mechanisms of establishing and maintaining tolerance, tolerance is not absolute. We hypothesize that it is possible to direct an effective response against tumors by inducing an autoimmune response to organ-specific antigens. To examine this hypothesis, we will use transgenic mice lines we have developed which specifically express human PSA in the prostate and investigate how this expression affects their ability to generate CTL responses to human PSA using novel immunization strategies. In this light, we have been working on developing novel viral vectors for immunization. Helper free herpes amplicons, plasmid based vectors that have an extremely large coding capacity, are attractive viral vaccine candidates for expressing recombinant proteins in vivo for immunization. The amplicon system has particular promise since it encodes no viral gene products and we have shown it very effectively infects dendritic cells. In collaboration with Edith Lord and in conjunction with Tom Foster's laboratory in the Department of Imaging Sciences, we have devised imaging approaches to look at the early steps in immunization and at the effector T cells generated. These studies will contribute to the rational design of immunotherapy for tumors as well as for HIV. We also believe that many of the techniques and approaches will be applicable to other infectious agents as well. In this regard, we are collaborating with investigators at University of North Carolina to identify T cell epitopes of Francisella tularensis. Francisella tularensis (FT) is a gram negative bacterium that is able to infect a wide range of mammalian hosts. FT has several properties that suggest could be developed as a biological weapon, including its ability to be aerosolized and its low LD50. Indeed, it has been asserted that FT was used as a bioweapon in World War II. Unfortunately relatively little information is available concerning the detailed cellular mechanism of resistance to re-infection either in humans or in experimental animals. However, as expected for a pathogen that grows largely intracellularly, T cells are believed to be a critical component in resistance to reinfection and recovery from primary infection. My laboratory has developed a technique called the TCAD ( the T-Cell antigen discovery technique) to identify and improve T cell epitopes, originally in the context of tumor vaccines. We have recently modified this system to large-scale screens for the identification of T cell epitopes from FT using this system which takes advantage of the tremendously enhanced efficiency particulate antigen cross-priming and a novel reporter system of T cell activation. It is hoped that the identification of the T cell epitopes recognized will yield to a batter understanding of the nature of a protective response and ultimately a defined vaccine.

Patents

Prostate Specific Regulatory Nucleic Acid Sequences and Transgenic Non-Human Animals Expressing Prostate Specific Antigen

Issue date: August 08, 2000

Patent #: 6,100,444

Country: United States

Inventors: Richard K Barth, John G Frelinger, Chungwen Wei

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: 1346036

Country: Europe

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 24, 2008

Patent #: 2002246625

Country: Australia

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: February 21, 2012

Patent #: 8,119,118

Country: United States

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: IE1346036

Country: Ireland

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: GB1346036

Country: United Kingdom

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: DK1346036

Country: Denmark

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpes Virus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: BE1346036

Country: Belgium

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpesvirus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: DE1346036

Country: Germany

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Helper Virus-Free Herpesvirus Amplicon Particles and Uses Thereof

Issue date: April 28, 2010

Patent #: FR1346036

Country: France

Inventors: William J Bowers, Stephen Dewhurst, Thomas G Evans, Howard J Federoff, John G Frelinger, Peter K Hocknell, Joseph D Rosenblatt, Khaled A Tolba, Richard A Willis

Protease Activated Cytokines

Issue date: May 27, 2014

Patent #: 8,734,774

Country: United States

Inventors: John G Frelinger, Baek Kim, John Puskas, Mark A Sullivan

Publications

Journal Articles

Instant Pot for antigen retrieval: a simple, safe and economical method for use in immunohistochemistry.

Kearns N, Norville K, Frelinger JG

BioTechniques.. 2023 May 74 (5):237-241. Epub 05/18/2023.

A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms.

Norville K, Skrombolas D, Ferry SL, Kearns N, Frelinger JG

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.. 2022 July 42 (7):316-328. Epub 1900 01 01.

Editorial: The Present and Future of Immunology Education.

Bottaro A, Brown DM, Frelinger JG

Frontiers in immunology.. 2021 12 :744090. Epub 08/02/2021.

Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.

Skrombolas D, Sullivan M, Frelinger JG

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.. 2019 April 39 (4):233-245. Epub 03/08/2019.

Inoculating a New Generation: Immunology in Medical Education

Haidaris, C. G.; Frelinger, J. G.;.

2019; 10: 2548.

Inoculating a New Generation: Immunology in Medical Education.

Haidaris CG, Frelinger JG

Frontiers in immunology.. 2019 10 :2548. Epub 11/01/2019.

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.

Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS

Oncoimmunology.. 2016 May 5 (5):e1116675. Epub 02/11/2016.

Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.

Skrombolas D, Wylie I, Maharaj S, Frelinger JG

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.. 2015 September 35 (9):690-7. Epub 05/04/2015.

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.

Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS

Nature communications.. 2015 June 256 :7458. Epub 06/25/2015.

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

Skrombolas D, Frelinger JG

Expert review of clinical immunology.. 2014 February 10 (2):207-17. Epub 1900 01 01.

Generation of a dual-functioning antitumor immune response in the peritoneal cavity.

Sedlacek AL, Gerber SA, Randall TD, van Rooijen N, Frelinger JG, Lord EM

The American journal of pathology.. 2013 October 183 (4):1318-1328. Epub 08/08/2013.

IFN-? mediates the antitumor effects of radiation therapy in a murine colon tumor.

Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM

The American journal of pathology.. 2013 June 182 (6):2345-54. Epub 04/12/2013.

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM

Immunology.. 2013 March 138 (3):280-92. Epub 1900 01 01.

Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Yokota SJ, Facciponte JG, Kelleher RJ, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB

Cancer immunity. 2013 13 :11. Epub 05/31/2013.

A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG

Journal of immunological methods.. 2011 October 28373 (1-2):111-26. Epub 08/18/2011.

Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.

Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J

Immunology.. 2011 June 133 (2):206-20. Epub 03/23/2011.

Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.

Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG

Immunology.. 2011 March 132 (3):348-60. Epub 01/07/2011.

A broadly applicable approach to T cell epitope identification: Application to improving tumor associated epitopes and identifying epitopes in complex pathogens

Journal of Immunological Methods (in press). 2011; .

IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Sorensen EW, Gerber SA, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2010 February 15184 (4):1858-66. Epub 01/08/2010.

An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.

Valentino M, Frelinger J

Immunologic research.. 2009 December 45 (2-3):218-28. Epub 02/11/2009.

Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Valentino MD, Hensley LL, Skrombolas D, McPherson PL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG

Molecular immunology.. 2009 May 46 (8-9):1830-8. Epub 02/23/2009.

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2008 March 1180 (5):3132-9. Epub 1900 01 01.

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo.

Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC

Vaccine.. 2007 April 3025 (17):3270-6. Epub 01/22/2007.

Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Santos K, Duke CM, Rodriguez-Colon SM, Dakwar A, Fan S, Keefer MC, Federoff HJ, Frelinger JG, Bowers WJ, Dewhurst S

Vaccine.. 2007 February 1925 (9):1634-46. Epub 11/15/2006.

Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.

Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG

Human gene therapy.. 2007 February 18 (2):93-105. Epub 1900 01 01.

In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.

Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J

Transplantation.. 2007 January 2783 (2):159-66. Epub 1900 01 01.

Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.

Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG, Foster TH

Molecular cancer therapeutics.. 2006 December 5 (12):3268-74. Epub 1900 01 01.

Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth.

Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM

The American journal of pathology.. 2006 November 169 (5):1739-52. Epub 1900 01 01.

Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals.

Wagner VE, Frelinger JG, Barth RK, Iglewski BH

Trends in microbiology.. 2006 February 14 (2):55-8. Epub 01/06/2006.

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2005 June 15174 (12):7516-23. Epub 1900 01 01.

Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.

Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM

The Prostate.. 2005 May 163 (2):105-16. Epub 1900 01 01.

Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy.

Bigelow CE, Vishwasrao HD, Frelinger JG, Foster TH

Journal of microscopy.. 2004 July 215 (Pt 1):24-33. Epub 1900 01 01.

Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo.

Mitra S, Goren EM, Frelinger JG, Foster TH

Photochemistry and photobiology.. 2003 December 78 (6):615-22. Epub 1900 01 01.

Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.

Moran JP, Gerber SA, Martin CA, Frelinger JG, Lord EM

International journal of cancer.. 2003 September 20106 (5):690-8. Epub 1900 01 01.

Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.

Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM

British journal of cancer.. 2003 May 688 (9):1453-61. Epub 1900 01 01.

Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.

Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG

The Prostate.. 2002 May 1551 (3):153-65. Epub 1900 01 01.

In vitro assay for site-specific proteases using bead-attached GFP substrate.

Patel D, Frelinger J, Goudsmit J, Kim B

BioTechniques.. 2001 November 31 (5):1194, 1196, 1198 passim. Epub 1900 01 01.

Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.

Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG

Human gene therapy.. 2001 October 1012 (15):1867-79. Epub 1900 01 01.

T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.

Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG

Journal of immunological methods.. 2001 October 1256 (1-2):107-19. Epub 1900 01 01.

Tumours can act as adjuvants for humoral immunity.

Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM

Immunology.. 2001 April 102 (4):486-97. Epub 1900 01 01.

Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies.

Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S

Archives of virology.. 2001 146 (9):1705-22. Epub 1900 01 01.

In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy.

Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Storozynsky E, Lord EM, Frelinger JG, Woodward JG

The Journal of immunology : official journal of the American Association of Immunologists.. 2000 May 1164 (9):4543-50. Epub 1900 01 01.

Alteration of tumour response to radiation by interleukin-2 gene transfer.

Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM

British journal of cancer.. 2000 February 82 (4):937-44. Epub 1900 01 01.

Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.

Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB

Journal of immunological methods.. 2000 January 13233 (1-2):57-65. Epub 1900 01 01.

Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.

Martin BK, Frelinger JG, Ting JP

The Journal of immunology : official journal of the American Association of Immunologists.. 1999 June 1162 (11):6663-70. Epub 1900 01 01.

Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.

Storozynsky E, Woodward JG, Frelinger JG, Lord EM

Immunology.. 1999 May 97 (1):138-49. Epub 1900 01 01.

The Roman god Janus: a paradigm for the function of CD43.

Ostberg JR, Barth RK, Frelinger JG

Immunology today.. 1998 December 19 (12):546-50. Epub 1900 01 01.

Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.

Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG

International journal of molecular medicine.. 1998 October 2 (4):487-96. Epub 1900 01 01.

IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.

Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 1998 June 15160 (12):5773-80. Epub 1900 01 01.

IL-3-mediated enhancement of particulate antigen presentation by macrophages.

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG

Journal of immunotherapy.. 1998 May 21 (3):205-10. Epub 1900 01 01.

Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.

Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM

Cancer research.. 1998 April 158 (7):1478-85. Epub 1900 01 01.

Tumor immunotherapy: cytokines and antigen presentation.

Lord EM, Frelinger JG

Cancer immunology, immunotherapy : CII.. 1998 April 46 (2):75-81. Epub 1900 01 01.

A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).

Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG

International journal of molecular medicine.. 1998 February 1 (2):379-86. Epub 1900 01 01.

Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens.

Ostberg JR, Dragone LL, Borrello MA, Phipps RP, Barth RK, Frelinger JG

European journal of immunology.. 1997 September 27 (9):2152-9. Epub 1900 01 01.

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1997 June 1094 (12):6369-74. Epub 1900 01 01.

Anti-CD43 inhibition of T cell homing.

McEvoy LM, Sun H, Frelinger JG, Butcher EC

The Journal of experimental medicine.. 1997 April 21185 (8):1493-8. Epub 1900 01 01.

Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency.

Ostberg JR, Dragone LL, Driskell T, Moynihan JA, Phipps R, Barth RK, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1996 December 1157 (11):4876-84. Epub 1900 01 01.

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.

Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG

Cancer immunology, immunotherapy : CII.. 1996 July 42 (6):362-8. Epub 1900 01 01.

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.

Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1996 April 1693 (8):3669-74. Epub 1900 01 01.

Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.

McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM

Cellular immunology.. 1995 October 15165 (2):183-92. Epub 1900 01 01.

B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.

Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM

Cellular immunology.. 1995 October 15165 (2):217-24. Epub 1900 01 01.

Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.

McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG

International journal of cancer.. 1995 May 2961 (5):628-34. Epub 1900 01 01.

Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival.

Dragone LL, Barth RK, Sitar KL, Disbrow GL, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1995 January 1792 (2):626-30. Epub 1900 01 01.

Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes.

McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.. 1994 April 15 (3):155-64. Epub 1900 01 01.

Isolation and expansion of tumor-infiltrating lymphocytes.

Woods ML, McAdam AJ, Frelinger JG, Lord EM

BioTechniques.. 1993 December 15 (6):970-2. Epub 1900 01 01.

Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2.

McAdam AJ, Yeh KY, Pulaski BA, Frelinger JG, Lord EM

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.. 1993 November 14 (4):293-7. Epub 1900 01 01.

Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG

Cancer research.. 1993 May 153 (9):2112-7. Epub 1900 01 01.

Thy 1+ dendritic epidermal cells but not Langerhans cells express Ly 48.

Gaspari AA, Ferbel B, Frelinger JG

The Journal of investigative dermatology.. 1993 March 100 (3):247-53. Epub 1900 01 01.

Differential epitope expression of Ly-48 (mouse leukosialin).

Baecher-Allan CM, Kemp JD, Dorfman KS, Barth RK, Frelinger JG

Immunogenetics.. 1993 37 (3):183-92. Epub 1900 01 01.

CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.

McAdam AJ, Blieden TM, Frelinger JG, Lord EM

European journal of immunology.. 1992 September 22 (9):2461-4. Epub 1900 01 01.

Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma.

Cerosaletti KM, Woodward JG, Lord EM, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1992 February 15148 (4):1212-21. Epub 1900 01 01.

CD43 is expressed normally on Wiskott-Aldrich-derived lymphocytes.

Dragone L, Pallant A, Insel R, Frelinger JG

Experimental and clinical immunogenetics.. 1992 9 (3):130-40. Epub 1900 01 01.

Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.

Blieden TM, McAdam AJ, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 1991 August 15147 (4):1433-8. Epub 1900 01 01.

Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors.

Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger JG, Lord EM

International journal of cancer. Supplement = Journal international

The nucleotide sequence of Ly 48 (mouse leukosialin, sialophorin): the mouse homolog of CD43.

Dorfman KS, Litaker W, Baecher CM, Frelinger JG

Nucleic acids research.. 1990 August 2518 (16):4932. Epub 1900 01 01.

Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha.

Phipps RP, Baecher C, Frelinger JG, Penney DP, Keng P, Brown D

European journal of immunology.. 1990 August 20 (8):1723-7. Epub 1900 01 01.

CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA.

Pallant A, Fukuda M, Frelinger JG

European journal of immunology.. 1990 July 20 (7):1423-8. Epub 1900 01 01.

Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.

Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM

Cellular immunology.. 1990 May 127 (2):299-310. Epub 1900 01 01.

cDNA cloning and localization of the mouse leukosialin gene (Ly48) to chromosome 7.

Baecher CM, Dorfman KS, Mattei MG, Frelinger JG

Immunogenetics.. 1990 31 (5-6):307-14. Epub 1900 01 01.

Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.

Pallant A, Eskenazi A, Mattei MG, Fournier RE, Carlsson SR, Fukuda M, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1989 February 86 (4):1328-32. Epub 1900 01 01.

Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.

Bahler DW, Cerosaletti KM, Lord EM, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1988 June 1140 (11):4003-12. Epub 1900 01 01.

Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens.

Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1988 April 1140 (7):2472-5. Epub 1900 01 01.

Identification and characterization of a mouse cell surface antigen with alternative molecular forms.

Baecher CM, Infante AJ, Semcheski KL, Frelinger JG

Immunogenetics.. 1988 28 (5):295-302. Epub 1900 01 01.

Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection.

Bahler DW, Frelinger JG, Harwell LW, Lord EM

Proceedings of the National Academy of Sciences of the United States of America.. 1987 July 84 (13):4562-6. Epub 1900 01 01.

Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes.

Sawicki JA, Frelinger JG, Palmer M, Buck DA, Dietzschold B, Wettstein PJ

The Journal of immunology : official journal of the American Association of Immunologists.. 1985 October 135 (4):2853-8. Epub 1900 01 01.

An analysis of monoclonal T cell and antibody recognition sites on Ia molecules.

Frelinger JG, Shigeta M, Fathman CG

The Journal of investigative dermatology.. 1985 July 85 (1 Suppl):30s-33s. Epub 1900 01 01.

Clonotypic antibodies which stimulate T cell clone proliferation.

Frelinger J, Sing A, Infante A, Fathman CG

Immunological reviews.. 1984 October 81 :21-38. Epub 1900 01 01.

Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity.

Frelinger JG, Shigeta M, Infante AJ, Nelson PA, Pierres M, Fathman CG

The Journal of experimental medicine.. 1984 March 1159 (3):704-15. Epub 1900 01 01.

T-lymphocyte clones.

Fathman CG, Frelinger JG

Annual review of immunology.. 1983 1 :633-55. Epub 1900 01 01.

T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies.

Beck BN, Frelinger JG, Shigeta M, Infante AJ, Cummings D, Hämmerling G, Fathman CG

The Journal of experimental medicine.. 1982 October 1156 (4):1186-94. Epub 1900 01 01.

A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains.

Steinmetz M, Moore KW, Frelinger JG, Sher BT, Shen FW, Boyse EA, Hood L

Cell.. 1981 September 25 (3):683-92. Epub 1900 01 01.

Analyses of RT1 products using two-dimensional polyacrylamide gels.

Frelinger JG, Hood L, Wettstein P

Transplantation proceedings.. 1981 June 13 (2):1360-3. Epub 1900 01 01.

Serologic and biochemical analyses of rat class II molecules with anti-Ia sera.

Wettstein PJ, Frelinger JG, Hood L

Transplantation proceedings.. 1981 June 13 (2):1364-6. Epub 1900 01 01.

Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes.

Steinmetz M, Frelinger JG, Fisher D, Hunkapiller T, Pereira D, Weissman SM, Uehara H, Nathenson S, Hood L

Cell.. 1981 April 24 (1):125-34. Epub 1900 01 01.

Peptide map comparisons of epidermal and spleen H-2 molecules.

Frelinger JG, Frelinger JA, Hood L

Immunogenetics.. 1981 March 112 (5-6):569-77. Epub 1900 01 01.

Serological and biochemical characterization of rat (RT1) class II molecules with restricted mouse anti-Ia sera.

Wettstein PJ, Frelinger JG, Hood L

Immunogenetics.. 1981 13 (1-2):93-107. Epub 1900 01 01.

Bone marrow origin of Ia molecules purified from epidermal cells.

Frelinger JA, Frelinger JG

The Journal of investigative dermatology.. 1980 July 75 (1):68-70. Epub 1900 01 01.

Structure of Ia antigens from the rat. Mouse alloantisera demonstrate at least two distinct molecular species.

Blankenhorn EP, Cecka JM, Frelinger J, Götze D, Hood L

European journal of immunology.. 1980 February 10 (2):145-51. Epub 1900 01 01.

Mouse epidermal Ia molecules have a bone marrow origin.

Frelinger JG, Hood L, Hill S, Frelinger JA

Nature.. 1979 November 15282 (5736):321-3. Epub 1900 01 01.

Effects of Chloramphenicol on the Circadian Rhythm of Neurospora crassa.

Frelinger JG, Motulsky H, Woodward DO

Plant physiology.. 1976 October 58 (4):592-4. Epub 1900 01 01.